Imaging February 7, 2025

Cardiology in the Spotlight: Enterprise Imaging That Goes Beyond Radiology February 7, 2025

The future of medical imaging is about connection. Today’s healthcare challenges demand platforms that unify radiology, cardiology, digital pathology, genomics, and beyond into a seamless enterprise ecosystem—moving past the era of standalone systems and isolated workflows. A complete enterprise imaging solution allows us to move closer to an improved multidisciplinary collaboration, and a more comprehensive […]

Artificial Intelligence April 21, 2025

How AI is Expanding ECG and Echo’s Applications April 21, 2025

Building stronger evidence for AI’s place in cardiology, this week brought several examples of how AI can improve ECG use cases and automate Echo for new disease detection methods. Starting with AI improving ECG for coronary revascularization, a deep learning ECG model outperformed both clinician-led ECG and troponin T testing in predicting which ED patients […]

Cardiology Pharmaceuticals April 17, 2025

Verve Vaults Forward From Topline Results April 17, 2025

Completing its pharma comeback story, Verve Therapeutics announced successful results from the Heart-2 Phase 1b Clinical Trial of its in-vivo base editing drug, VERVE-102, that targets the PCSK9 gene for reducing LDL-C. VERVE-102’s topline results come from a small group of 14 patients across three different dose cohorts (weight-based cohorts of 0.3, 0.45, and 0.6mg/kg) […]

Cardiology Pharmaceuticals April 14, 2025

At Home Nasal Sprays and PSVT ER Visits April 14, 2025

Data analysis from the NODE-301 Phase 3 trial suggests that patients self-adminstering Milestone Pharmaceuticals’ etripamil (CARDAMYST) might be able to avoid ER visits for paroxysmal supraventricular tachycardia (PSVT). Sniffing around for proof of etripamil’s effectiveness, researchers analyzed data from parts 1 and 2 of the NODE-301 trial and found that patients who self-administered the drug […]

More Stories

Cardiology Practices April 10, 2025

Does Value Based Care Improve Cardiology? April 10, 2025

Casting doubt on value based cardiac care, a JAMA study found that outpatient cardiology practices enrolled in an accountable care organization (ACO) through the Medicare Shared Savings Program (MSSP) don’t offer better care than non-ACO practices. Evaluating the ACO incentives, researchers compared care quality data from the ACC’s NCDR PINNACLE Registry before and 6-12 months […]

Atrial Fibrillation April 7, 2025

PFA or Cryoballoon for Paroxysmal AFib? April 7, 2025

Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. In one of the first PFA versus cryoballoon head-to-heads, researchers randomized 210 patients with symptomatic paroxysmal AFib to undergo PFA with Boston Scientific’s Farapulse […]

Cardiology April 3, 2025

The Top Trends of ACC.25 April 3, 2025

The ACC 2025 meeting is all wrapped up after matching the attendance and excitement of last year’s expo, with a clear trend toward better diagnostics and even better pharmaceuticals. Among dozens of highlights, here are Cardiac Wire’s seven biggest trends from ACC.25. The Takeaway From software and hardware innovations in the exhibit hall to strong […]

Surgeries & Interventions March 31, 2025

Abbott Enters Burgeoning IVL Segment March 31, 2025

Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but it’s now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbott’s new IVL Investigational Device Exemption (IDE) from the FDA. Abbott’s new IVL IDE was two years in the making following its $890M acquisition of Cardiovascular Systems in 2023 […]

Cardiology Pharmaceuticals March 27, 2025

Ezetimibe Plus Statins Equals Better Outcomes March 27, 2025

New results from a vast Mayo Clinic meta-analysis suggest that combining ezetimibe with statins to lower LDL-C could have significant mortality and MACE benefits over statin monotherapy. Digging through decades of data from PubMed, Embase, and ClinicalTrials.gov, researchers pooled all relevant articles published through June 2024 (108k patients) and found that a combination lipid-lowering therapy […]

Cardiology Pharmaceuticals March 24, 2025

Amvuttra Arrives for ATTR-CM with a High Asking Price March 24, 2025

It’s not surprising that Alnylam’s Amvuttra (vutrisiran) received FDA approval for ATTR-CM last week, but what shocked many was Alnylam’s choice to price the drug at nearly half a million dollars per year in a segment where its incumbent competitors cost half as much. Alnylam claims Amvuttra’s eyewatering price stems from the drug’s “compelling and […]

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!